Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Sep;64(3):451–456. doi: 10.1038/bjc.1991.330

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.

V M Macaulay 1, I E Smith 1, M J Everard 1, J D Teale 1, J C Reubi 1, J L Millar 1
PMCID: PMC1977656  PMID: 1654981

Abstract

We have detected somatostatin receptors (SSR) by autoradiography in 3/4 established small cell lung cancer (SCLC) cell lines but not in two non-SCLC cell lines. The growth of 1/3 SSR positive SCLC cell lines was significantly inhibited by the long-acting somatostatin analogue octreotide (SMS 201-995, Sandostatin) 10(-9) M. We treated 20 SCLC patients with octreotide 250 micrograms three times daily for 1 week prechemotherapy (six patients) or at relapse after chemotherapy (14). Octreotide was well tolerated, and serum insulin-like growth factor-I levels were suppressed to 62 +/- 7% of pre-treatment levels. However there was no evidence of anti-tumour activity measured by tumour bulk or serum levels of neuron-specific enolase. In one patient metastatic skin nodules were shown to be SSR positive before and at the end of 2 weeks octreotide. Despite this the patient had progressive disease, and tumour cells obtained by fine needle aspirate before and after treatment showed no growth inhibition when cultured with octreotide immediately or following establishment as a cell line. In summary we saw little correlation between SSR expression and growth inhibition by octreotide, either in vitro or clinically.

Full text

PDF
451

Images in this article

454Figure 4
on p.454

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belasco J. B., Mitchell C. D., Rohrbaugh T., Rosenstock J. IV melphalan in children. Cancer Treat Rep. 1987 Dec;71(12):1277–1278. [PubMed] [Google Scholar]
  2. Bloom S. R., Polak J. M. Somatostatin. Br Med J (Clin Res Ed) 1987 Aug 1;295(6593):288–290. doi: 10.1136/bmj.295.6593.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bogden A. E., Taylor J. E., Moreau J. P., Coy D. H., LePage D. J. Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). Cancer Res. 1990 Jul 15;50(14):4360–4365. [PubMed] [Google Scholar]
  4. Carney D. N., Gazdar A. F., Bepler G., Guccion J. G., Marangos P. J., Moody T. W., Zweig M. H., Minna J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 1985 Jun;45(6):2913–2923. [PubMed] [Google Scholar]
  5. Carney D. N., Marangos P. J., Ihde D. C., Bunn P. A., Jr, Cohen M. H., Minna J. D., Gazdar A. F. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13;1(8272):583–585. doi: 10.1016/s0140-6736(82)91748-2. [DOI] [PubMed] [Google Scholar]
  6. Carney D. N., Teeling M. Neuron-specific enolase: how useful as a cancer marker? Eur J Cancer Clin Oncol. 1988 May;24(5):825–828. doi: 10.1016/0277-5379(88)90190-3. [DOI] [PubMed] [Google Scholar]
  7. D'Ercole A. J., Stiles A. D., Underwood L. E. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A. 1984 Feb;81(3):935–939. doi: 10.1073/pnas.81.3.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Duchesne G. M., Eady J. J., Peacock J. H., Pera M. F. A panel of human lung carcinoma lines: establishment, properties and common characteristics. Br J Cancer. 1987 Sep;56(3):287–293. doi: 10.1038/bjc.1987.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  10. Gorden P., Comi R. J., Maton P. N., Go V. L. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med. 1989 Jan 1;110(1):35–50. doi: 10.7326/0003-4819-110-1-35. [DOI] [PubMed] [Google Scholar]
  11. Kraenzlin M. E., Ch'ng J. L., Wood S. M., Carr D. H., Bloom S. R. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology. 1985 Jan;88(1 Pt 1):185–187. doi: 10.1016/s0016-5085(85)80153-0. [DOI] [PubMed] [Google Scholar]
  12. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  13. Lamberts S. W., Uitterlinden P., Schuijff P. C., Klijn J. G. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin Endocrinol (Oxf) 1988 Oct;29(4):411–420. doi: 10.1111/j.1365-2265.1988.tb02890.x. [DOI] [PubMed] [Google Scholar]
  14. Lamberts S. W., Uitterlinden P., del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 1987 Oct;65(4):703–710. doi: 10.1210/jcem-65-4-703. [DOI] [PubMed] [Google Scholar]
  15. Liebow C., Reilly C., Serrano M., Schally A. V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A. 1989 Mar;86(6):2003–2007. doi: 10.1073/pnas.86.6.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Macaulay V. M., Everard M. J., Teale J. D., Trott P. A., Van Wyk J. J., Smith I. E., Millar J. L. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res. 1990 Apr 15;50(8):2511–2517. [PubMed] [Google Scholar]
  17. Macaulay V. M., Teale J. D., Everard M. J., Joshi G. P., Millar J. L., Smith I. E. Serum insulin-like growth factor-I levels in patients with small cell lung cancer. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1241–1242. doi: 10.1016/0277-5379(88)90135-6. [DOI] [PubMed] [Google Scholar]
  18. Macaulay V., Joshi G. P., Everard M., Smith I. E., Millar J. L. A high molecular weight non-bombesin/gastrin releasing peptide growth factor in small cell lung cancer. Br J Cancer. 1987 Dec;56(6):791–794. doi: 10.1038/bjc.1987.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Macauly V. M., Teale J. D., Everard M. J., Joshi G. P., Smith I. E., Millar J. L. Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. Br J Cancer. 1988 Jan;57(1):91–93. doi: 10.1038/bjc.1988.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  21. Minuto F., Del Monte P., Barreca A., Alama A., Cariola G., Giordano G. Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line. Cancer Res. 1988 Jul 1;48(13):3716–3719. [PubMed] [Google Scholar]
  22. Moreau J. P., DeFeudis F. V. Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and perspectives. Life Sci. 1987 Feb 2;40(5):419–437. doi: 10.1016/0024-3205(87)90107-x. [DOI] [PubMed] [Google Scholar]
  23. Nõu E., Steinholtz L., Bergh J., Nilsson K., Påhlman S. Neuron-specific enolase as a follow-up marker in small cell bronchial carcinoma. A prospective study in an unselected series. Cancer. 1990 Mar 15;65(6):1380–1385. doi: 10.1002/1097-0142(19900315)65:6<1380::aid-cncr2820650622>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  24. Parmar H., Bogden A., Mollard M., de Rougé B., Phillips R. H., Lightman S. L. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev. 1989 Jun;16(2):95–115. doi: 10.1016/0305-7372(89)90013-3. [DOI] [PubMed] [Google Scholar]
  25. Pollak M. N., Polychronakos C., Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 1989 Jul-Aug;9(4):889–891. [PubMed] [Google Scholar]
  26. Reubi J. C., Horisberger U., Lang W., Koper J. W., Braakman R., Lamberts S. W. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol. 1989 Feb;134(2):337–344. [PMC free article] [PubMed] [Google Scholar]
  27. Reubi J. C., Landolt A. M. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab. 1984 Dec;59(6):1148–1151. doi: 10.1210/jcem-59-6-1148. [DOI] [PubMed] [Google Scholar]
  28. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  29. Reubi J. C., Rivier J., Perrin M., Brown M., Vale W. Specific high affinity binding sites for somatostatin-28 on pancreatic beta-cells: differences with brain somatostatin receptors. Endocrinology. 1982 Mar;110(3):1049–1051. doi: 10.1210/endo-110-3-1049. [DOI] [PubMed] [Google Scholar]
  30. Reubi J. C., Waser B., Sheppard M., Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer. 1990 Feb 15;45(2):269–274. doi: 10.1002/ijc.2910450211. [DOI] [PubMed] [Google Scholar]
  31. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  32. Sorenson G. D., Pettengill O. S., Brinck-Johnsen T., Cate C. C., Maurer L. H. Hormone production by cultures of small-cell carcinoma of the lung. Cancer. 1981 Mar 15;47(6):1289–1296. doi: 10.1002/1097-0142(19810315)47:6<1289::aid-cncr2820470610>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  33. Srkalovic G., Cai R. Z., Schally A. V. Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab. 1990 Mar;70(3):661–669. doi: 10.1210/jcem-70-3-661. [DOI] [PubMed] [Google Scholar]
  34. Taylor J. E., Bogden A. E., Moreau J. P., Coy D. H. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun. 1988 May 31;153(1):81–86. doi: 10.1016/s0006-291x(88)81192-6. [DOI] [PubMed] [Google Scholar]
  35. Taylor J. E., Coy D. H., Moreau J. P. High affinity binding of [125I-Tyr11]somatostatin-14 to human small cell lung carcinoma (NCI-H69). Life Sci. 1988;43(5):421–427. doi: 10.1016/0024-3205(88)90521-8. [DOI] [PubMed] [Google Scholar]
  36. Teale J. D., Marks V. Inappropriately elevated plasma insulin-like growth factor II in relation to suppressed insulin-like growth factor I in the diagnosis of non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf) 1990 Jul;33(1):87–98. doi: 10.1111/j.1365-2265.1990.tb00469.x. [DOI] [PubMed] [Google Scholar]
  37. Teale J. D., Marks V. The measurement of insulin-like growth factor I: clinical applications and significance. Ann Clin Biochem. 1986 Jul;23(Pt 4):413–424. doi: 10.1177/000456328602300406. [DOI] [PubMed] [Google Scholar]
  38. Weber C., Merriam L., Koschitzky T., Karp F., Benson M., Forde K., LoGerfo P. Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery. 1989 Aug;106(2):416–422. [PubMed] [Google Scholar]
  39. del Pozo E., Neufeld M., Schlüter K., Tortosa F., Clarenbach P., Bieder E., Wendel L., Nüesch E., Marbach P., Cramer H. Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh) 1986 Apr;111(4):433–439. doi: 10.1530/acta.0.1110433. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES